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BRIEF REPORT
New use of prescription drugs prior to a cancer diagnosis
Anton Pottegård1* and Jesper Hallas1,2
1Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark
2Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
ABSTRACT
Purpose Cancers often have considerable induction periods. This confers a risk of reverse causation bias in studies of cancer risk associ-
ated with drug use, as early symptoms of a yet undiagnosed cancer might lead to drug treatment in the period leading up to the diagnosis.
This bias can be alleviated by disregarding exposure for some time before the cancer diagnosis (lag time). We aimed at assessing the duration
of lag time needed to avoid reverse causation bias.
Methods We identiﬁed all Danish patients with incident cancer between 2000 and 2012 (n= 353 087). Incident use of prescription drugs
was assessed prior to their cancer diagnosis as well as among population controls (n= 1 402 400). Analyses were conducted for all cancers
and for breast, lung, colon and prostate cancer individually. Further, analyses were performed for a composite measure of all incident drug
use as well as for nine pre-speciﬁed individual drug classes, representing drug treatment likely to be prescribed for symptoms of the given
cancers.
Results The incidence rate for new drug treatment among cancer cases was stable around 130 per 1000 persons per month until 6months
prior to cancer diagnosis where it increased gradually and peaked at 434 in the month immediately preceding the cancer diagnosis. Consid-
erable variation was observed among cancers, for example, breast cancer showed almost no such effect. The pre-selected drug classes
showed a stronger increase prior to cancer diagnoses than drugs overall.
Conclusions Incident use of drugs increases in the months prior to a cancer diagnosis. To avoid reverse causation, 6months’ lag time
would be sufﬁcient for most drug-cancer associations. © 2016 The Authors. Pharmacoepidemiology and Drug Safety published by John
Wiley & Sons Ltd.
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INTRODUCTION
Many cancers have considerable induction periods, and
patients will therefore often have a lengthy pre-
diagnostic period.1 A yet undiagnosed cancer might
cause symptoms that are misinterpreted as benign ill-
ness. For example, gastrointestinal cancers might give
rise to abdominal pain, which is treated with, for exam-
ple, proton pump inhibitors or laxatives, before any at-
tempts of diagnostic work-up are made. Further, the
more frequent health care contact for the individual pa-
tient leading up to the diagnosis might in itself lead to
the initiation of drug treatment, for example, the clinical
work-upmight reveal a previously undiagnosed diabetic
condition or hypertension, which then leads to initiation
of new drug therapy. Both of these factors might be
observed as an increase in new drug treatments given
to patients before their cancer diagnosis.
Such a drug use pattern would have implications for
pharmacoepidemiological studies of cancer risk asso-
ciated with use of drugs. In these studies, onset of
new drug treatment prior to diagnosis raises the possi-
bility for reverse causation bias.2 For example, if we
were to study the association between proton pump in-
hibitors and gastric cancer, we might ﬁnd an associa-
tion solely attributable to the fact that early cancer
symptoms (before the diagnosis is made) are
misinterpreted as acid related disorders and treated
with proton-pump inhibitors. The conventional ap-
proach to this reverse causation problem is to disre-
gard a certain period (lag time) before the cancer
diagnosis when accounting for drug exposure.3,4 This
solution is applicable both in cohort and case-control
designs. To our knowledge, however, there has been
no systematic appraisal of this phenomenon.
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In this study, we aimed to inform the choice of lag-
time period in studies on drug–cancer associations to
avoid reverse causation bias. We did so using the
Danish nationwide health registries on cancer5 and pre-
scription drugs6 to investigate the onset of new drug
treatments in the period leading up to a cancer diagnosis.
METHODS
Sampling all Danish patients with incident cancer
between 2000 and 2012, we assessed drug use in a
24-month window prior to the date of cancer diagno-
sis. Drug use patterns among cancer cases were com-
pared with the drug use among population controls,
matched to cases by sex, age and calendar time.
Study population
Using the Danish Cancer Registry,5 we identiﬁed all
incident cancer cases in Denmark between 2000 and
2012. For each cancer case, we identiﬁed four popula-
tion controls, matched on sex, age and calendar time
(date of the case diagnosis). For both cancer cases
and the population controls, we excluded children,
individuals with a prior cancer diagnosis (except
non-melanoma skin cancer) and individuals that had
migrated in or out of Denmark within the last 10years.
Drug use
Incident drug use was deﬁned as an individual’s ﬁrst-
ever ﬁlling of a prescription drug according to the
Danish National Prescription Registry,6 deﬁning drugs
at the level of the single substance. As the registry
holds data from 1995, this ensured a minimum of
5years prescription data when identifying new users.
For cancer cases and population controls, we assessed
incident use of prescription drugs in monthly intervals
relative to the date of the cancer diagnosis (or day of
sampling for controls), going back 24months. In each
month, we estimated the incidence rate (IR) of drug
use by—within that month—counting the number of
new drug treatments and dividing by follow-up among
cancer cases (or population controls), thus calculating
the IR with a unit of new treatments per person-month.
Analysis
In an overall analysis, the IR for any new drug treat-
ment was calculated in the 2years preceding any can-
cer diagnosis and compared with that of population
controls. Similar analyses were carried out speciﬁcally
for the four most common cancers: lung, breast, pros-
tate and colon cancer. Lastly, we performed the
analysis on these four types of cancer for six pre-
speciﬁed drug classes, selected as drugs that could
likely be prescribed for symptoms for a given cancer:
drugs against overactive bladder and drugs against pros-
tatic hyperplasia (possibly associatedwith a later diagno-
sis of prostate cancer), inhaled beta-agonists and cough
suppressants (lung cancer), and drugs against constipa-
tion or diarrhoea and proton pump inhibitors (colon can-
cer). No relevant drug could be identiﬁed for early
symptoms of breast cancer. Furthermore, we included
use of opioids, which is possibly related to all cancer di-
agnoses, as well as oral antidiabetics and statins, as
markers for drugs that might be initiated following
health care contacts. For a full list of deﬁnitions for these
drugs, see Appendix A. In these analyses, we only con-
sidered individuals at risk for incident drug use, that is
we disregarded those with ever-use of the drugs in ques-
tion prior to the time window of assessment.
RESULTS
We identiﬁed 353087 eligible cancer cases that were
matched to 1402400 population controls. The four
most common types of cancer were breast
(n=51774), colon (n=29505), lung (n=45509) and
prostate cancer (n=41115).
In all analyses, the pattern of incident drug use was
very similar between cancer cases and populations con-
trols in the time period of 24 to 12months prior to cancer
diagnosis. Thus, only results from the 12-month win-
dow prior to diagnosis are presented throughout.
The overall IR for new drug treatment among all can-
cer cases was stable around 130 per 1000 persons per
month until 6months prior to cancer diagnosis where
it increased and peaked at 434 new drug treatments
per 1000 persons per month in the month immediately
Figure 1. Number of new drug treatments per 1000 persons per month in
a 12-month window prior to cancer diagnosis among cancer cases and com-
pared with the pattern among age- and sex-matched population controls.
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Figure 2. Number of new drug treatments per 1000 persons per month in a 12-month window prior to cancer diagnosis among breast, colon, prostate and
lung cancer cases, compared with the pattern among age- and sex-matched population controls.
Figure 3. Number of new drug treatments per 1000 persons per month in a 12-month window prior to cancer diagnosis among cancer cases for pre-selected
drug classes. Note the logarithmic Y-axis.
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preceding the cancer diagnosis (Figure 1). This pattern
varied considerably between the four most common
cancers (Figure 2): Almost no increase was observed
for breast cancer cases, while prostate, colon and lung
cancer peaked at 397, 428 and 741 new drug treatments
per 1000 persons per month in the month prior to cancer
diagnosis, respectively. No noticeable changes were ob-
served among the population controls.
The pre-selected site-speciﬁc drugs all showed a no-
ticeable increase prior to cancer diagnosis (Figure 3).
New use of the three non-speciﬁc drugs included in the
analysis all showed an increase prior to cancer diagnosis,
especially opioid analgesics, which increased prior to all
cancers except breast cancer, most pronounced for lung
cancer, increasing 15-fold and peaking at 70 new drug
treatments per 1000 per month (Figure 3).
In a post hoc analysis, we explored the drug classes
contributing to the increased overall IR observed among
cases. For the 6-month time window prior to the cancer
diagnosis, we calculated cumulative incidence propor-
tions (risks) for incident use of individual drug classes
(fourth ATC-level, e.g. A02BC proton pump inhibi-
tors), while restricting to those at risk, that is, never users
of these drugs by the start of the time window. We re-
ported the 20 drug classes with the largest absolute risk
difference, comparing cancer cases to population con-
trols. The results for all cancers (Table 1), showed that
the increase in drug use was driven by proton pump in-
hibitors, analgesics and antibiotics. Similar analyses for
the four most common cancers (eTable1a-d), showed
that the increased drug use was driven by therapy either
speciﬁc to the individual cancer, such as laxatives prior
to a colon cancer diagnosis, or related to cancer diagno-
ses in general (analgesics and antibiotics).
DISCUSSION
Our study demonstrated a very clear increase in new
drug use in the months preceding a cancer diagnosis.
We have demonstrated both a speciﬁc and an unspe-
ciﬁc component, the ﬁrst apparently related to speciﬁc
symptoms of the cancers, the second probably to unre-
lated conditions revealed during frequent physician
contacts before the cancer diagnosis. The pattern dif-
fers between cancers. For most drug-cancer associa-
tions, six months’ lag time appears to be sufﬁcient to
avoid substantial reverse causation.
Our study has several strengths. The Danish cancer
registry has virtually complete and valid registration
of all cancers in a well-deﬁned, stable population,5
and the prescription registry has offered complete cov-
erage of the Danish population since 1995.6 Among
the weaknesses is that we cannot account for the
handling of the earliest cancer symptoms in primary
care. However, we ﬁnd it unlikely that GPs to any
great extent would treat for example colon cancer-
related abdominal pain with proton pump inhibitors
if they suspected the pain to be cancer-related. Diag-
nostic process delay is unlikely to play a major role;
according to Danish law, there is an expedited diag-
nostic work-up if a cancer suspicion is voiced.
In general, there are two reasons to apply lag time in
studies of drug–cancer associations; the problem of re-
verse causation as demonstrated in this paper and the
fact that exposure immediately before the cancer diag-
nosis usually cannot be considered as contributing to
the development of the cancer. By including such eti-
ologically irrelevant exposure, true associations would
be attenuated. At least for colon7 and prostate8 cancer,
there is good evidence of a long latency from ﬁrst can-
cer development to a clinically overt cancer.
The potential downside of applying lag time in a
drug–cancer study relates to the concept of drugs as a
cancer promotor,9 that is exposures that may mediate
Table 1. Analysis of the 20 individual drug classes with the largest abso-
lute difference in the 6-month risk of incident use comparing cases (all can-
cers) to population controls.
Risk Absolute
risk
difference
(%)ATC Drug class
Cases
(%)
Controls
(%)
A02BC Proton pump inhibitors 6.8 1.6 5.2
J01CA Penicillins with
extended spectrum
6.9 2.1 4.8
N02AX Other opioids 6.0 1.5 4.4
J01CE Beta-lactamase sensitive
penicillins
7.6 4.0 3.6
J01FA Macrolides 4.5 1.7 2.8
N02AA Natural opium alkaloids 3.5 0.9 2.6
M01AE Propionic acid
derivatives
5.1 2.5 2.6
N02BE Anilides 4.0 1.7 2.3
A03FA Propulsives 2.6 0.4 2.1
N05CF Benzodiazepine related
drugs
3.0 0.8 2.1
M01AB Acetic acid derivatives
and related substances
3.5 1.5 2.0
J01MA Fluoroquinolones 2.4 0.7 1.7
J01EB Short-acting
sulfonamides
2.6 0.9 1.7
N05BA Benzodiazepine
derivatives
2.3 0.6 1.7
H02AB Glucocorticoids 2.6 1.0 1.6
C03CA Sulfonamides, plain 2.3 0.9 1.4
A12BA Potassium 2.1 0.8 1.3
A06AD Osmotically acting
laxatives
1.8 0.5 1.2
G04CA Alpha-adrenoreceptor
antagonists
1.6 0.3 1.2
R05DA Opium alkaloids and
derivatives
2.0 0.8 1.2
Notes:
ATC =Anatomical-Therapeutical-Chemical
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late critical steps in carcinogenesis. Empirically, this
may appear as a relatively short interval between expo-
sure and clinically overt cancer. If we routinely apply
lag time in all analyses, we would overlook such associ-
ations. Late-stage cancer promotion has been demon-
strated for some immunomodulating drugs10
particularly in patients with organ transplant, where ex-
posure as short as six months may trigger a clinical can-
cer diagnosis.11 Other good examples are, however,
quite rare, especially associated with such shortness of
exposure. Researchers are encouraged to explore the ex-
posure pattern leading up to a cancer diagnosis in a
given study, to inform the choice of lag-time.
We conclude that lag time should be considered in
studies of drug–cancer associations and that 6months
is usually sufﬁcient to avoid reverse causation bias.
However, sound clinical reasoning should prevail
concerning the manifestations of the speciﬁc cancers.
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KEY POINTS
• Cancers that are not yet diagnosed may cause
symptoms that are confused with benign diseases
and treated as such.
• This may result in reverse causation bias,
whereby drug treatment that precedes the cancer
diagnosis may be suspected of causing the can-
cer, while in reality it is used to treat early cancer
symptoms. The bias can be alleviated by
disregarding exposure for some time before the
cancer diagnosis (lag time).
• Reverse causation has two components; a speciﬁc
one that is related to the cancer’s early symptoms
and an unspeciﬁc one that is related to frequent
physician contact before the cancer diagnosis.
• Our study demonstrated both components, the
speciﬁc being the dominant.
• Our data suggests that for most cancers, six
months of lag time is sufﬁcient to avoid reverse
causation bias.
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